| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonadotropin-Releasing Hormone | 41 | 2020 | 217 | 4.870 |
Why?
|
| Androgens | 17 | 2022 | 181 | 4.830 |
Why?
|
| Testosterone | 23 | 2023 | 416 | 4.480 |
Why?
|
| Adrenal Cortex Neoplasms | 14 | 2026 | 70 | 4.030 |
Why?
|
| Adrenocortical Carcinoma | 15 | 2026 | 72 | 3.940 |
Why?
|
| Pituitary Neoplasms | 13 | 2025 | 190 | 2.780 |
Why?
|
| Endocrinology | 8 | 2025 | 77 | 2.320 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2020 | 143 | 2.240 |
Why?
|
| Neurons | 23 | 2020 | 1652 | 2.110 |
Why?
|
| Adenoma | 10 | 2025 | 218 | 2.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 9 | 2014 | 231 | 2.020 |
Why?
|
| Sexual Dysfunction, Physiological | 6 | 2019 | 75 | 1.780 |
Why?
|
| Pituitary Gland | 10 | 2018 | 149 | 1.670 |
Why?
|
| Mitotane | 2 | 2024 | 10 | 1.640 |
Why?
|
| Hormone Replacement Therapy | 4 | 2022 | 107 | 1.370 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 12 | 1.290 |
Why?
|
| Periodicals as Topic | 5 | 2016 | 209 | 1.290 |
Why?
|
| Follicle Stimulating Hormone | 17 | 2024 | 266 | 1.280 |
Why?
|
| Cell Movement | 13 | 2025 | 961 | 1.260 |
Why?
|
| Sexual Dysfunctions, Psychological | 3 | 2019 | 30 | 1.260 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2018 | 625 | 1.230 |
Why?
|
| Estradiol | 15 | 2024 | 515 | 1.220 |
Why?
|
| Reproduction | 5 | 2011 | 208 | 1.200 |
Why?
|
| Oncogene Proteins | 6 | 2008 | 62 | 1.170 |
Why?
|
| Cadherins | 2 | 2024 | 200 | 1.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2025 | 376 | 1.120 |
Why?
|
| Luteinizing Hormone | 15 | 2023 | 207 | 1.100 |
Why?
|
| Postmenopause | 8 | 2019 | 394 | 1.090 |
Why?
|
| Hyperandrogenism | 2 | 2021 | 25 | 0.980 |
Why?
|
| Dehydroepiandrosterone | 6 | 2022 | 49 | 0.960 |
Why?
|
| Endocrinologists | 1 | 2025 | 12 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2025 | 1450 | 0.920 |
Why?
|
| Hypogonadism | 6 | 2014 | 93 | 0.900 |
Why?
|
| Adrenal Cortex | 4 | 2020 | 33 | 0.900 |
Why?
|
| Endocrine System Diseases | 1 | 2025 | 35 | 0.890 |
Why?
|
| Publishing | 3 | 2015 | 114 | 0.890 |
Why?
|
| Neuroendocrine Tumors | 2 | 2024 | 119 | 0.880 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2026 | 936 | 0.860 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2024 | 12 | 0.840 |
Why?
|
| Gene Expression Regulation | 14 | 2015 | 2601 | 0.800 |
Why?
|
| Ovary | 8 | 2024 | 234 | 0.800 |
Why?
|
| Anilides | 1 | 2024 | 84 | 0.800 |
Why?
|
| Promoter Regions, Genetic | 13 | 2012 | 1247 | 0.780 |
Why?
|
| Contraception | 1 | 2025 | 170 | 0.780 |
Why?
|
| Consensus | 3 | 2020 | 478 | 0.780 |
Why?
|
| Humans | 122 | 2026 | 145750 | 0.770 |
Why?
|
| Gonadotrophs | 6 | 2015 | 21 | 0.760 |
Why?
|
| Pyridines | 3 | 2024 | 609 | 0.740 |
Why?
|
| Hypothalamus | 9 | 2011 | 163 | 0.710 |
Why?
|
| Cell Line, Tumor | 15 | 2026 | 3551 | 0.690 |
Why?
|
| Cell Proliferation | 13 | 2026 | 2514 | 0.690 |
Why?
|
| Animals | 64 | 2026 | 38100 | 0.670 |
Why?
|
| Anovulation | 1 | 2021 | 9 | 0.670 |
Why?
|
| Societies, Medical | 6 | 2019 | 900 | 0.670 |
Why?
|
| Neurosurgical Procedures | 4 | 2020 | 202 | 0.660 |
Why?
|
| Bicycling | 1 | 2021 | 117 | 0.650 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2017 | 85 | 0.640 |
Why?
|
| Eunuchism | 1 | 2020 | 3 | 0.620 |
Why?
|
| Cell Survival | 10 | 2025 | 1103 | 0.610 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2021 | 188 | 0.600 |
Why?
|
| Mice | 31 | 2026 | 18357 | 0.590 |
Why?
|
| Estrogens | 7 | 2022 | 367 | 0.590 |
Why?
|
| Acromegaly | 2 | 2020 | 17 | 0.580 |
Why?
|
| Sexual Maturation | 4 | 2014 | 48 | 0.580 |
Why?
|
| Female | 69 | 2026 | 79025 | 0.570 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2026 | 981 | 0.560 |
Why?
|
| Hypopituitarism | 3 | 2014 | 16 | 0.560 |
Why?
|
| Membrane Proteins | 3 | 2025 | 1166 | 0.550 |
Why?
|
| Cell Line | 17 | 2015 | 2823 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 5 | 2026 | 1582 | 0.520 |
Why?
|
| Andropause | 2 | 2014 | 5 | 0.520 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 41 | 0.510 |
Why?
|
| Desmosomes | 1 | 2017 | 22 | 0.510 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2015 | 18 | 0.470 |
Why?
|
| Receptors, Somatostatin | 1 | 2015 | 24 | 0.460 |
Why?
|
| Adipocytes | 1 | 2017 | 223 | 0.460 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 64 | 0.450 |
Why?
|
| Repressor Proteins | 2 | 2015 | 429 | 0.450 |
Why?
|
| Erectile Dysfunction | 4 | 1999 | 38 | 0.440 |
Why?
|
| Antibodies | 1 | 2017 | 397 | 0.440 |
Why?
|
| Drug Repositioning | 2 | 2025 | 39 | 0.440 |
Why?
|
| Serial Publications | 1 | 2014 | 2 | 0.440 |
Why?
|
| Premenopause | 4 | 2019 | 125 | 0.430 |
Why?
|
| Signal Transduction | 14 | 2025 | 5223 | 0.430 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2014 | 20 | 0.430 |
Why?
|
| Apoptosis | 11 | 2026 | 2443 | 0.420 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2018 | 199 | 0.420 |
Why?
|
| Biological Assay | 1 | 2014 | 132 | 0.410 |
Why?
|
| Editorial Policies | 1 | 2014 | 45 | 0.410 |
Why?
|
| Human Growth Hormone | 1 | 2014 | 47 | 0.410 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 207 | 0.390 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 453 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2015 | 440 | 0.390 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2013 | 15 | 0.390 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 2219 | 0.380 |
Why?
|
| Endocrine Glands | 2 | 2010 | 14 | 0.370 |
Why?
|
| Middle Aged | 31 | 2025 | 36297 | 0.370 |
Why?
|
| Male | 49 | 2025 | 72992 | 0.370 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 630 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 76 | 0.370 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2024 | 196 | 0.370 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2011 | 322 | 0.370 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2015 | 52 | 0.360 |
Why?
|
| Dihydrotestosterone | 3 | 2010 | 40 | 0.360 |
Why?
|
| Vagina | 1 | 2014 | 203 | 0.350 |
Why?
|
| Women's Health | 2 | 2019 | 316 | 0.350 |
Why?
|
| DNA-Binding Proteins | 5 | 2025 | 1482 | 0.350 |
Why?
|
| Antigens, Differentiation | 1 | 2011 | 76 | 0.340 |
Why?
|
| Bone Density | 4 | 2020 | 487 | 0.340 |
Why?
|
| Immunohistochemistry | 7 | 2018 | 1723 | 0.340 |
Why?
|
| Pituitary Apoplexy | 1 | 2011 | 1 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 136 | 0.340 |
Why?
|
| Veterans | 2 | 2023 | 1639 | 0.340 |
Why?
|
| Transcription Factors | 5 | 2025 | 1736 | 0.340 |
Why?
|
| Calcium-Binding Proteins | 2 | 2025 | 221 | 0.340 |
Why?
|
| Adult | 29 | 2026 | 40867 | 0.340 |
Why?
|
| Estrous Cycle | 1 | 2011 | 22 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 172 | 0.330 |
Why?
|
| Ovariectomy | 6 | 2024 | 166 | 0.330 |
Why?
|
| Estrone | 1 | 2010 | 41 | 0.330 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 740 | 0.320 |
Why?
|
| Models, Molecular | 1 | 2015 | 1599 | 0.320 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1996 | 149 | 0.310 |
Why?
|
| Glycoproteins | 1 | 2012 | 354 | 0.310 |
Why?
|
| Menstrual Cycle | 1 | 2010 | 145 | 0.300 |
Why?
|
| Aged | 20 | 2025 | 26212 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 6 | 2021 | 887 | 0.300 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 1211 | 0.290 |
Why?
|
| Brain Injuries | 3 | 2014 | 507 | 0.290 |
Why?
|
| Trans-Activators | 2 | 2021 | 396 | 0.290 |
Why?
|
| Transcription, Genetic | 6 | 2002 | 1454 | 0.290 |
Why?
|
| Steroidogenic Factor 1 | 2 | 2025 | 13 | 0.290 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 1512 | 0.280 |
Why?
|
| Kallmann Syndrome | 3 | 2020 | 7 | 0.280 |
Why?
|
| Rats | 24 | 2024 | 5585 | 0.280 |
Why?
|
| RNA, Messenger | 14 | 2011 | 2805 | 0.280 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 308 | 0.280 |
Why?
|
| Transcriptome | 4 | 2024 | 1043 | 0.270 |
Why?
|
| Stroke | 2 | 2014 | 1271 | 0.270 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 751 | 0.260 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 194 | 0.260 |
Why?
|
| Medroxyprogesterone | 1 | 2007 | 11 | 0.260 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2007 | 15 | 0.260 |
Why?
|
| Hirsutism | 2 | 2021 | 12 | 0.250 |
Why?
|
| Neurosecretory Systems | 1 | 2007 | 31 | 0.250 |
Why?
|
| Infertility | 1 | 2007 | 61 | 0.250 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1329 | 0.250 |
Why?
|
| Protein Binding | 6 | 2025 | 2240 | 0.250 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 1777 | 0.240 |
Why?
|
| Proteins | 3 | 2003 | 1023 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2181 | 0.240 |
Why?
|
| Global Health | 2 | 2019 | 403 | 0.240 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2026 | 39 | 0.240 |
Why?
|
| Neurogenesis | 3 | 2013 | 157 | 0.230 |
Why?
|
| Base Sequence | 11 | 2008 | 2171 | 0.230 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 264 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 457 | 0.230 |
Why?
|
| beta Catenin | 2 | 2025 | 254 | 0.230 |
Why?
|
| Cell Nucleus | 2 | 2015 | 588 | 0.230 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 337 | 0.230 |
Why?
|
| Prolactinoma | 2 | 2018 | 13 | 0.230 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2025 | 40 | 0.230 |
Why?
|
| Tumor Microenvironment | 3 | 2020 | 735 | 0.220 |
Why?
|
| Blood Coagulation | 1 | 2007 | 274 | 0.220 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2025 | 42 | 0.220 |
Why?
|
| Sphingolipids | 1 | 2025 | 83 | 0.220 |
Why?
|
| Transfection | 6 | 2015 | 927 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 6 | 2017 | 5992 | 0.220 |
Why?
|
| Body Composition | 5 | 2024 | 693 | 0.220 |
Why?
|
| Sulfasalazine | 1 | 2024 | 22 | 0.220 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2024 | 9 | 0.220 |
Why?
|
| Mice, Knockout | 4 | 2014 | 3130 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 383 | 0.210 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 777 | 0.210 |
Why?
|
| Young Adult | 8 | 2025 | 14250 | 0.210 |
Why?
|
| Energy Metabolism | 2 | 2024 | 935 | 0.210 |
Why?
|
| DNA | 10 | 2012 | 1437 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 288 | 0.200 |
Why?
|
| Vasodilation | 1 | 2007 | 521 | 0.200 |
Why?
|
| Up-Regulation | 4 | 2021 | 848 | 0.200 |
Why?
|
| Immunoconjugates | 1 | 2025 | 138 | 0.200 |
Why?
|
| Triamcinolone Acetonide | 1 | 2023 | 20 | 0.200 |
Why?
|
| Femur Neck | 2 | 2020 | 62 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2019 | 126 | 0.190 |
Why?
|
| Rare Diseases | 1 | 2024 | 116 | 0.190 |
Why?
|
| Cytoplasm | 2 | 2015 | 254 | 0.190 |
Why?
|
| Models, Biological | 4 | 2012 | 1764 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2190 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 592 | 0.190 |
Why?
|
| Rats, Wistar | 1 | 2024 | 450 | 0.190 |
Why?
|
| Anorexia | 1 | 2022 | 16 | 0.180 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 212 | 0.180 |
Why?
|
| Stress, Physiological | 2 | 2015 | 443 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2026 | 532 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17322 | 0.180 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2001 | 45 | 0.180 |
Why?
|
| Double-Blind Method | 4 | 2020 | 2064 | 0.170 |
Why?
|
| Genomics | 2 | 2024 | 831 | 0.170 |
Why?
|
| Aldosterone | 2 | 2019 | 42 | 0.170 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 638 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 157 | 0.170 |
Why?
|
| Immunoblotting | 3 | 2018 | 295 | 0.170 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2019 | 52 | 0.170 |
Why?
|
| Puberty, Precocious | 5 | 1992 | 12 | 0.170 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 139 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 4569 | 0.170 |
Why?
|
| Antigens, CD | 1 | 2024 | 558 | 0.170 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 61 | 0.160 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 149 | 0.160 |
Why?
|
| Receptors, Somatotropin | 1 | 2020 | 10 | 0.160 |
Why?
|
| Zebrafish Proteins | 2 | 2023 | 314 | 0.160 |
Why?
|
| Cells, Cultured | 7 | 2018 | 4151 | 0.160 |
Why?
|
| Somatostatin | 1 | 2020 | 53 | 0.160 |
Why?
|
| Dopamine Agonists | 1 | 2020 | 41 | 0.160 |
Why?
|
| Phthalazines | 1 | 2021 | 63 | 0.160 |
Why?
|
| Binding Sites | 3 | 2025 | 1311 | 0.160 |
Why?
|
| Pheochromocytoma | 1 | 2021 | 67 | 0.160 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 5 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2021 | 64 | 0.160 |
Why?
|
| Nuclear Proteins | 1 | 2025 | 740 | 0.160 |
Why?
|
| Receptors, Progesterone | 3 | 2003 | 244 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 484 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 981 | 0.150 |
Why?
|
| Benzamides | 1 | 2021 | 226 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 508 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 883 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2020 | 206 | 0.150 |
Why?
|
| Gene Expression | 4 | 2014 | 1478 | 0.150 |
Why?
|
| Transsexualism | 1 | 2019 | 19 | 0.150 |
Why?
|
| Hospital Medicine | 1 | 2021 | 97 | 0.150 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2019 | 10 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2019 | 51 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.150 |
Why?
|
| Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.140 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2018 | 12 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 194 | 0.140 |
Why?
|
| Lamin Type B | 1 | 2018 | 6 | 0.140 |
Why?
|
| Sphenoid Sinus | 1 | 2018 | 7 | 0.140 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Naphthyridines | 1 | 2018 | 20 | 0.140 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 165 | 0.140 |
Why?
|
| Pyrazoles | 2 | 2013 | 517 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2018 | 25 | 0.140 |
Why?
|
| Blotting, Northern | 4 | 2000 | 203 | 0.140 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 177 | 0.140 |
Why?
|
| Hyponatremia | 1 | 2018 | 43 | 0.130 |
Why?
|
| Molecular Sequence Data | 8 | 2000 | 2883 | 0.130 |
Why?
|
| Protein Kinase C | 3 | 1995 | 251 | 0.130 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2018 | 72 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 266 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2023 | 1897 | 0.130 |
Why?
|
| Gene Deletion | 3 | 2011 | 392 | 0.130 |
Why?
|
| Thermogenesis | 1 | 2017 | 45 | 0.130 |
Why?
|
| Prosencephalon | 3 | 2008 | 54 | 0.130 |
Why?
|
| Parathyroid Neoplasms | 3 | 2003 | 12 | 0.130 |
Why?
|
| Gonadotropins | 4 | 2003 | 44 | 0.130 |
Why?
|
| Microarray Analysis | 1 | 2017 | 117 | 0.130 |
Why?
|
| Recovery of Function | 2 | 2020 | 716 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 287 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 2018 | 164 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2012 | 1043 | 0.120 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 868 | 0.120 |
Why?
|
| Homeostasis | 2 | 2018 | 644 | 0.120 |
Why?
|
| Resistance Training | 2 | 2018 | 186 | 0.120 |
Why?
|
| Exercise | 3 | 2018 | 2203 | 0.120 |
Why?
|
| Pregnancy | 2 | 2025 | 7215 | 0.120 |
Why?
|
| Genes, jun | 1 | 1996 | 9 | 0.120 |
Why?
|
| DNA Damage | 2 | 2026 | 437 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 265 | 0.120 |
Why?
|
| Genes, fos | 1 | 1996 | 36 | 0.120 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 3 | 1990 | 23 | 0.120 |
Why?
|
| Adiposity | 2 | 2018 | 532 | 0.120 |
Why?
|
| Transgender Persons | 1 | 2019 | 210 | 0.120 |
Why?
|
| Leuprolide | 1 | 2015 | 21 | 0.110 |
Why?
|
| Dopamine | 1 | 2018 | 295 | 0.110 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 119 | 0.110 |
Why?
|
| Molecular Conformation | 1 | 2015 | 141 | 0.110 |
Why?
|
| Pituitary Gland, Anterior | 4 | 2007 | 37 | 0.110 |
Why?
|
| Sleep | 2 | 2020 | 889 | 0.110 |
Why?
|
| Histone Deacetylase 6 | 1 | 2015 | 17 | 0.110 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.110 |
Why?
|
| Testicular Diseases | 1 | 1995 | 6 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2026 | 534 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2015 | 56 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2015 | 105 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 42 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2024 | 11793 | 0.110 |
Why?
|
| Contraindications | 1 | 2014 | 90 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2019 | 1708 | 0.110 |
Why?
|
| Gene Amplification | 1 | 2015 | 118 | 0.110 |
Why?
|
| Societies, Scientific | 1 | 2014 | 50 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2020 | 697 | 0.110 |
Why?
|
| Hypothyroidism | 1 | 1995 | 68 | 0.100 |
Why?
|
| Reference Standards | 1 | 2014 | 177 | 0.100 |
Why?
|
| Publications | 1 | 2014 | 47 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 132 | 0.100 |
Why?
|
| DNA Primers | 3 | 2008 | 505 | 0.100 |
Why?
|
| Catalytic Domain | 1 | 2015 | 234 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2025 | 426 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2015 | 202 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1969 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 188 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 247 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2002 | 1184 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 1998 | 479 | 0.100 |
Why?
|
| Tubulin | 1 | 2015 | 146 | 0.100 |
Why?
|
| Menopause | 2 | 2007 | 326 | 0.100 |
Why?
|
| Chorionic Gonadotropin | 2 | 2011 | 78 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 992 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2019 | 789 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 21 | 0.100 |
Why?
|
| Cytoskeleton | 2 | 2007 | 192 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 33 | 0.100 |
Why?
|
| Olfactory Pathways | 2 | 2010 | 38 | 0.100 |
Why?
|
| Adolescent | 6 | 2020 | 22569 | 0.090 |
Why?
|
| Transcriptional Activation | 2 | 2007 | 372 | 0.090 |
Why?
|
| Professional Practice | 1 | 2013 | 57 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1751 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 298 | 0.090 |
Why?
|
| Aggression | 1 | 2014 | 180 | 0.090 |
Why?
|
| Pedigree | 1 | 2014 | 515 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1150 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 910 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 855 | 0.090 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2018 | 147 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2018 | 772 | 0.090 |
Why?
|
| Testis | 2 | 1990 | 162 | 0.090 |
Why?
|
| G2 Phase | 1 | 2012 | 39 | 0.090 |
Why?
|
| rac GTP-Binding Proteins | 2 | 2002 | 35 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 92 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 371 | 0.090 |
Why?
|
| Triptorelin Pamoate | 3 | 1986 | 19 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 117 | 0.090 |
Why?
|
| Cell Count | 2 | 2011 | 319 | 0.090 |
Why?
|
| Receptors, CCR5 | 1 | 2012 | 60 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2012 | 50 | 0.090 |
Why?
|
| Rats, Inbred Strains | 7 | 1990 | 321 | 0.090 |
Why?
|
| CpG Islands | 1 | 2012 | 171 | 0.090 |
Why?
|
| Indoles | 1 | 2015 | 507 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2015 | 583 | 0.090 |
Why?
|
| Reference Values | 3 | 2010 | 798 | 0.090 |
Why?
|
| Pituitary Hormones | 2 | 2008 | 15 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 178 | 0.090 |
Why?
|
| Libido | 2 | 2010 | 24 | 0.090 |
Why?
|
| Superovulation | 1 | 2011 | 8 | 0.090 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2011 | 10 | 0.090 |
Why?
|
| Genes, p53 | 1 | 2011 | 67 | 0.080 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 85 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 118 | 0.080 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2011 | 39 | 0.080 |
Why?
|
| Age Factors | 2 | 2014 | 3346 | 0.080 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 2 | 1990 | 10 | 0.080 |
Why?
|
| Thyroid Hormones | 2 | 2008 | 69 | 0.080 |
Why?
|
| Kisspeptins | 2 | 2007 | 5 | 0.080 |
Why?
|
| Integrases | 1 | 2011 | 122 | 0.080 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 80 | 0.080 |
Why?
|
| Precipitin Tests | 2 | 2002 | 90 | 0.080 |
Why?
|
| Cautery | 1 | 2010 | 4 | 0.080 |
Why?
|
| Amenorrhea | 2 | 2008 | 31 | 0.080 |
Why?
|
| Genes, Dominant | 2 | 2020 | 100 | 0.080 |
Why?
|
| Pituitary Hormones, Anterior | 2 | 2007 | 7 | 0.080 |
Why?
|
| Sphenoid Bone | 1 | 2010 | 15 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2023 | 8075 | 0.080 |
Why?
|
| Central Nervous System Cysts | 1 | 2010 | 13 | 0.080 |
Why?
|
| Cell Division | 1 | 2012 | 757 | 0.080 |
Why?
|
| Mutation | 4 | 2021 | 4090 | 0.080 |
Why?
|
| Flavonoids | 2 | 2002 | 85 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2025 | 191 | 0.080 |
Why?
|
| Follicle Stimulating Hormone, beta Subunit | 5 | 1990 | 31 | 0.080 |
Why?
|
| Infertility, Male | 1 | 1990 | 80 | 0.080 |
Why?
|
| Genes, Retinoblastoma | 2 | 2003 | 9 | 0.080 |
Why?
|
| Placenta | 2 | 1997 | 787 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 5 | 2003 | 187 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2025 | 741 | 0.080 |
Why?
|
| Quality of Life | 1 | 2022 | 3210 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 8346 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2002 | 821 | 0.070 |
Why?
|
| Estrus | 1 | 2008 | 16 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 450 | 0.070 |
Why?
|
| Cell Adhesion | 2 | 2014 | 451 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2007 | 231 | 0.070 |
Why?
|
| Thyrotropin | 3 | 2007 | 120 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2020 | 680 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2014 | 877 | 0.070 |
Why?
|
| Prognosis | 2 | 2019 | 4329 | 0.070 |
Why?
|
| Hypoxia | 1 | 2015 | 1199 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2010 | 225 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 1474 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 268 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2025 | 667 | 0.070 |
Why?
|
| Prolactin | 2 | 2007 | 87 | 0.070 |
Why?
|
| Carcinoma | 2 | 2003 | 227 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 572 | 0.060 |
Why?
|
| Protein Multimerization | 1 | 2008 | 205 | 0.060 |
Why?
|
| Zebrafish | 2 | 2023 | 532 | 0.060 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 42 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 138 | 0.060 |
Why?
|
| Phenotype | 3 | 2020 | 3170 | 0.060 |
Why?
|
| Orchiectomy | 5 | 1990 | 72 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2007 | 136 | 0.060 |
Why?
|
| Cognition | 2 | 2006 | 1271 | 0.060 |
Why?
|
| Research Design | 1 | 2013 | 1139 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2008 | 250 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2191 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 1191 | 0.060 |
Why?
|
| Affect | 2 | 2006 | 321 | 0.060 |
Why?
|
| Amines | 1 | 2026 | 40 | 0.060 |
Why?
|
| Age Determination by Skeleton | 1 | 1986 | 16 | 0.060 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 143 | 0.060 |
Why?
|
| Tretinoin | 1 | 2006 | 125 | 0.060 |
Why?
|
| HIV-1 | 1 | 2012 | 908 | 0.060 |
Why?
|
| Transcription Factor Pit-1 | 1 | 2025 | 26 | 0.060 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2025 | 18 | 0.060 |
Why?
|
| Thiazoles | 1 | 2026 | 142 | 0.060 |
Why?
|
| Ethanol | 1 | 2010 | 631 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 2006 | 79 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 1146 | 0.060 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2025 | 25 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 408 | 0.060 |
Why?
|
| Nerve Net | 1 | 2008 | 286 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 2028 | 0.060 |
Why?
|
| Restriction Mapping | 3 | 1995 | 81 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2025 | 63 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 404 | 0.050 |
Why?
|
| Receptors, LHRH | 1 | 2004 | 14 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 198 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2004 | 33 | 0.050 |
Why?
|
| MEF2 Transcription Factors | 2 | 2001 | 51 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 979 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 3915 | 0.050 |
Why?
|
| Adipose Tissue, White | 1 | 2024 | 43 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 11 | 0.050 |
Why?
|
| Neurites | 1 | 2004 | 50 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2003 | 15 | 0.050 |
Why?
|
| Floxuridine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2025 | 122 | 0.050 |
Why?
|
| Time Factors | 5 | 2019 | 7133 | 0.050 |
Why?
|
| Genes, BRCA2 | 1 | 2003 | 33 | 0.050 |
Why?
|
| DNA Probes | 3 | 1992 | 59 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2023 | 53 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2024 | 238 | 0.050 |
Why?
|
| Pentobarbital | 1 | 2003 | 17 | 0.050 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2003 | 10 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2025 | 337 | 0.050 |
Why?
|
| Discrimination Learning | 1 | 2003 | 53 | 0.050 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 1062 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2003 | 72 | 0.050 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 172 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 70 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2023 | 135 | 0.050 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2002 | 59 | 0.040 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2002 | 13 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2002 | 56 | 0.040 |
Why?
|
| COS Cells | 1 | 2002 | 177 | 0.040 |
Why?
|
| Reading | 1 | 2003 | 135 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2002 | 277 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2002 | 91 | 0.040 |
Why?
|
| Aurora Kinase B | 1 | 2021 | 10 | 0.040 |
Why?
|
| Environmental Pollutants | 1 | 2003 | 139 | 0.040 |
Why?
|
| Mental Recall | 1 | 2003 | 223 | 0.040 |
Why?
|
| Sequence Deletion | 2 | 2002 | 191 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 58 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2002 | 151 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2002 | 129 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 222 | 0.040 |
Why?
|
| Caspases | 1 | 2001 | 233 | 0.040 |
Why?
|
| Protein Transport | 1 | 2002 | 442 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2020 | 54 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 331 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 372 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 354 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2000 | 335 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 98 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2024 | 461 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2002 | 199 | 0.040 |
Why?
|
| Ligands | 1 | 2002 | 668 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 376 | 0.040 |
Why?
|
| Indolizines | 1 | 2019 | 13 | 0.040 |
Why?
|
| Body Height | 2 | 1995 | 203 | 0.040 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Body Weight | 1 | 2024 | 972 | 0.040 |
Why?
|
| Cerebellum | 1 | 2001 | 224 | 0.040 |
Why?
|
| Progesterone | 2 | 2019 | 215 | 0.040 |
Why?
|
| Attention | 1 | 2003 | 463 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 65 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 97 | 0.040 |
Why?
|
| Penile Erection | 1 | 1999 | 7 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 41 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 1999 | 77 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 729 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 285 | 0.040 |
Why?
|
| Androstadienes | 1 | 1999 | 77 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 167 | 0.040 |
Why?
|
| Kinetics | 3 | 1992 | 1568 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 442 | 0.040 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2018 | 7 | 0.040 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1998 | 35 | 0.040 |
Why?
|
| Sequence Homology | 1 | 1998 | 43 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1996 | 157 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 153 | 0.030 |
Why?
|
| Gender Identity | 1 | 2019 | 129 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 442 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2019 | 162 | 0.030 |
Why?
|
| Actigraphy | 1 | 2019 | 148 | 0.030 |
Why?
|
| Cortisone | 1 | 2018 | 16 | 0.030 |
Why?
|
| Cell Death | 1 | 2020 | 382 | 0.030 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 89 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2024 | 686 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 277 | 0.030 |
Why?
|
| Disease | 1 | 1999 | 96 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1998 | 273 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 337 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 307 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 554 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2021 | 305 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 228 | 0.030 |
Why?
|
| Hip Joint | 1 | 2019 | 173 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 431 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 351 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 198 | 0.030 |
Why?
|
| Octamer Transcription Factor-6 | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sirolimus | 1 | 1999 | 282 | 0.030 |
Why?
|
| Vitamin D | 1 | 2020 | 404 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1261 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 2667 | 0.030 |
Why?
|
| Cell Communication | 1 | 1999 | 328 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1996 | 66 | 0.030 |
Why?
|
| DNA Footprinting | 1 | 1996 | 33 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 849 | 0.030 |
Why?
|
| Leadership | 1 | 2021 | 402 | 0.030 |
Why?
|
| HIV Infections | 1 | 2012 | 3195 | 0.030 |
Why?
|
| Spodoptera | 1 | 1996 | 40 | 0.030 |
Why?
|
| Leucine Zippers | 1 | 1996 | 13 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1996 | 73 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 538 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 618 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2018 | 298 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1996 | 362 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2018 | 365 | 0.030 |
Why?
|
| Luciferases | 1 | 1996 | 154 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 1996 | 79 | 0.030 |
Why?
|
| Aging | 1 | 2006 | 1973 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 778 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1899 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2019 | 495 | 0.030 |
Why?
|
| Neuropeptides | 1 | 1995 | 75 | 0.030 |
Why?
|
| Brain | 2 | 2000 | 2969 | 0.030 |
Why?
|
| E-Selectin | 1 | 2014 | 61 | 0.030 |
Why?
|
| Adrenal Glands | 2 | 1992 | 76 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 875 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2014 | 99 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1994 | 23 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 838 | 0.030 |
Why?
|
| Half-Life | 1 | 1994 | 155 | 0.030 |
Why?
|
| Loss of Heterozygosity | 2 | 2003 | 52 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 6084 | 0.020 |
Why?
|
| Staurosporine | 1 | 1992 | 22 | 0.020 |
Why?
|
| Gonads | 1 | 1992 | 22 | 0.020 |
Why?
|
| Alkaloids | 1 | 1992 | 28 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 475 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1992 | 16 | 0.020 |
Why?
|
| Choriocarcinoma | 1 | 1992 | 9 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 1044 | 0.020 |
Why?
|
| Feedback | 2 | 1990 | 180 | 0.020 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 410 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2013 | 147 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 43 | 0.020 |
Why?
|
| RNA | 1 | 1998 | 912 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2011 | 25 | 0.020 |
Why?
|
| Cavernous Sinus | 1 | 2011 | 16 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2013 | 328 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2001 | 696 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 611 | 0.020 |
Why?
|
| Puberty | 1 | 1992 | 137 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 1992 | 98 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1992 | 309 | 0.020 |
Why?
|
| Skull Base | 1 | 2011 | 55 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 1992 | 762 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 220 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 428 | 0.020 |
Why?
|
| Radiography | 2 | 2011 | 853 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 923 | 0.020 |
Why?
|
| Mortality | 1 | 2013 | 380 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 1990 | 14 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2014 | 667 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2013 | 6032 | 0.020 |
Why?
|
| Psychomotor Performance | 2 | 2004 | 324 | 0.020 |
Why?
|
| Algorithms | 1 | 1998 | 1850 | 0.020 |
Why?
|
| Ejaculation | 1 | 1990 | 11 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2019 | 2447 | 0.020 |
Why?
|
| Vaginismus | 1 | 2010 | 1 | 0.020 |
Why?
|
| Norpregnenes | 1 | 2010 | 4 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 14 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 344 | 0.020 |
Why?
|
| Dyspareunia | 1 | 2010 | 8 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 325 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1990 | 170 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1218 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1992 | 666 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 688 | 0.020 |
Why?
|
| Psychology | 1 | 2010 | 86 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1986 | 43 | 0.020 |
Why?
|
| Rehabilitation Centers | 1 | 2009 | 39 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1988 | 15 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 232 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 5921 | 0.020 |
Why?
|
| Physical Examination | 1 | 2010 | 244 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 244 | 0.020 |
Why?
|
| Receptors, Kisspeptin-1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Netrin-1 | 1 | 2007 | 17 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 68 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1990 | 452 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2007 | 86 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2007 | 79 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 91 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 750 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2003 | 2525 | 0.020 |
Why?
|
| Child | 6 | 2010 | 22738 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 1985 | 14 | 0.010 |
Why?
|
| Food, Formulated | 1 | 1985 | 16 | 0.010 |
Why?
|
| Intestinal Polyps | 1 | 1985 | 14 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2018 | 2977 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 444 | 0.010 |
Why?
|
| Leydig Cells | 1 | 1985 | 15 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 1491 | 0.010 |
Why?
|
| Jaw Neoplasms | 1 | 2003 | 3 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 1985 | 159 | 0.010 |
Why?
|
| Mifepristone | 1 | 2003 | 54 | 0.010 |
Why?
|
| Signal Detection, Psychological | 1 | 2003 | 25 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 33 | 0.010 |
Why?
|
| Inflammation | 1 | 2014 | 2883 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2003 | 165 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1985 | 258 | 0.010 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Host Cell Factor C1 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 381 | 0.010 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2003 | 60 | 0.010 |
Why?
|
| Response Elements | 1 | 2002 | 86 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1986 | 788 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 2933 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2001 | 81 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2001 | 117 | 0.010 |
Why?
|
| Reaction Time | 1 | 2003 | 434 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 216 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1300 | 0.010 |
Why?
|
| Potassium | 1 | 2001 | 152 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 610 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 2003 | 269 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 867 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 399 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 2460 | 0.010 |
Why?
|
| Growth Hormone | 2 | 1989 | 91 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1986 | 5428 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1990 | 2131 | 0.010 |
Why?
|
| Decision Making | 1 | 2003 | 981 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 60 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 1994 | 61 | 0.010 |
Why?
|
| Alleles | 1 | 1994 | 896 | 0.010 |
Why?
|
| Follicular Phase | 1 | 1990 | 41 | 0.010 |
Why?
|
| Ovulation Induction | 1 | 1990 | 65 | 0.000 |
Why?
|
| Densitometry | 1 | 1990 | 36 | 0.000 |
Why?
|
| Propylthiouracil | 1 | 1989 | 6 | 0.000 |
Why?
|
| Blotting, Southern | 1 | 1989 | 85 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1989 | 55 | 0.000 |
Why?
|
| Child, Preschool | 3 | 1992 | 11866 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1989 | 168 | 0.000 |
Why?
|
| Molecular Structure | 1 | 1990 | 487 | 0.000 |
Why?
|
| Introns | 1 | 1989 | 256 | 0.000 |
Why?
|
| RNA Probes | 1 | 1987 | 12 | 0.000 |
Why?
|
| Affinity Labels | 1 | 1987 | 16 | 0.000 |
Why?
|
| Exons | 1 | 1989 | 364 | 0.000 |
Why?
|
| Biotin | 1 | 1987 | 32 | 0.000 |
Why?
|
| Azides | 1 | 1987 | 49 | 0.000 |
Why?
|
| Cattle | 1 | 1989 | 946 | 0.000 |
Why?
|
| Ovarian Cysts | 1 | 1986 | 6 | 0.000 |
Why?
|
| Hypothalamic Neoplasms | 1 | 1986 | 9 | 0.000 |
Why?
|
| Hamartoma | 1 | 1986 | 29 | 0.000 |
Why?
|
| Bone Development | 1 | 1986 | 52 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1986 | 197 | 0.000 |
Why?
|
| Enema | 1 | 1985 | 46 | 0.000 |
Why?
|
| Uterus | 1 | 1986 | 228 | 0.000 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1986 | 317 | 0.000 |
Why?
|
| Energy Intake | 1 | 1985 | 512 | 0.000 |
Why?
|